SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Disappointing results and outlooks from major tech companies, alongside concerns that heavy AI infrastructure spending may not deliver sufficient returns, have fueled a broad risk-off mood and pressure on the S&P 500. Traders are divided between calling it the start of a deeper AI-led correction and viewing the selloff as a buying opportunity.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker fourth-quarter outlook, citing soft PC demand and supply constraints, drove a sharp selloff despite stronger-than-expected quarterly results. Traders are split between viewing the drop as an overreaction and buying the dip, and seeing the guidance and execution risks as signs of further weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure after Amazons heavy AI infrastructure spending and Intels weak outlook intensified concerns about tech-sector earnings and whether AI investment will generate adequate returns. Traders are debating whether the selloff signals a broader AI-trade unwind or a buying opportunity, with panic over further losses competing with calls to buy the dip.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and outlook drew scrutiny as slight revenue and earnings misses, heavy AI infrastructure spending, and weaker cash flow fueled a sharp selloff. Traders are divided: some see spending and uncertain returns as a risk, while others argue strong AWS growth supports the investment and view the drop as an overreaction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Weak Amazon results and Intel guidance have intensified a broader AI and semiconductor selloff, prompting debate over whether hyperscaler spending will generate adequate returns; some traders counter that ongoing cloud growth and investment still support chip demand. The community is also discussing allegations linking a Singapore cloud customer to Chinese intelligence, which Nvidia has rejected as a concern about ordinary business dealings.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks strong quarterly results and raised outlook, alongside its announced 8-for-1 stock split, dominate discussion. Traders are debating the sharp selloff despite the beat: some blame broader tech and AI risk-off sentiment or profit-taking, while bullish voices point to robust data-center demand and question whether the market reaction reflects the companys fundamentals.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated lifileucel lung-cancer trial results drove a sharp selloff: the overall response rate was broadly in line with the prior update, while a small, retrospectively identified biomarker subgroup showed a much higher response rate. Traders are split between viewing the subgroup as a promising precision-treatment strategy and worrying that it leaves regulatory approval, the addressable market, and the timeline less certain; many also criticized managements presentation of the data.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep slide to fresh lows, with traders criticizing its business prospects and describing the stock as a speculative vehicle tied to Trump. Discussion also centers on the approaching midterms: many expect political risk to weigh on the shares, while some bulls argue a Republican showing could support a rebound.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples resilience as investors rotate away from AI-heavy tech into a perceived safe haven is the dominant topic, with many traders describing it as an anti-AI hedge supporting the broader market. Bulls see defensive appeal and limited AI spending as strengths, while bears cite a stretched valuation, upcoming earnings risk, and concerns about new-device demand and quality.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategys Q3 results prompted debate over Bitcoin-driven earnings gains versus softer revenue, while traders also focused on the CFO transition. Much of the bearish reaction centers on the suspected Binance hack and Bitcoin selloff, though some traders view the decline as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?

DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Guggenheim Reiterates Buy Rating for DBV Technologies (NASDAQ:DBVT)

Guggenheim reiterated a "buy" rating and issued a $51.00 target price on shares of DBV Technologies in a research report on Monday...

What is HC Wainwright's Estimate for DBVT FY2029 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Equities research analysts at HC Wainwright decreased their FY2029 earnings estimates for shares of DBV Technologies in a research note issued on Friday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $0...

DBV Technologies (NASDAQ:DBVT) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of DBV Technologies from a 'sell' rating to a 'hold' rating in a research note on Saturday...

DBV Technologies (NASDAQ:DBVT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Citizens Jmp boosted their price target on DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday...

DBV Technologies (NASDAQ:DBVT) Posts Quarterly Earnings Results, Misses Estimates By $0.41 EPS

DBV Technologies (NASDAQ:DBVT - Get Free Report) posted its earnings results on Thursday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the firm, Marketbeat Ratings reports...

DBV Technologies (DBVT) to Release Quarterly Earnings on Wednesday

DBV Technologies (NASDAQ:DBVT) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 29. (View Earnings Report at...

DBV Technologies (NASDAQ:DBVT) Shares Pass Above Fifty Day Moving Average   - Time to Sell?

DBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50 Day Moving Average - Should You Sell...

$DBVT Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.70 up 41.67% YoY
• Reported revenue of $1.6M down -42.86% YoY
• DBV Technologies estimates its existing cash and cash equivalents will fund operations into the third quarter of 2027; as of September 30, 2026, cash and equivalents totaled $165.7M.

Stocktwits

DBV Technologies

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.70 up 41.67% YoY
• Reported revenue of $1.6M down -42.86% YoY
• DBV Technologies estimates its existing cash and cash equivalents will fund operations into the third quarter of 2027; as of September 30, 2026, cash and equivalents totaled $165.7M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.70 up 41.67% YoY
• Reported revenue of $1.6M down -42.86% YoY
• DBV Technologies estimates its existing cash and cash equivalents will fund operations into the third quarter of 2027; as of September 30, 2026, cash and equivalents totaled $165.7M.

DBV Technologies reported substantial doubt about its ability to continue as a going concern and requires additional capital; quarterly losses widened as operating expenses rose, while sole-source manufacturing faces FDA cGMP remediation risk.

DBV Technologies submitted its 4-through-7-year-old VIASKIN Peanut BLA supported by the 654-child VITESSE study, is advancing toddler development, and is preparing U.S. launch and dedicated manufacturing capacity.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

DBV Technologies - ADR

DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>VIASKIN patch is designed to introduce microgram amounts of an allergen like peanuts to the immune system through intact skin to induce tolerance.</li><li>The company now plans to submit an application to the U.S. Food and Drug Administration seeking approval for Viaskin Peanut in the first half of 2026.</li><li>The company expects its application might be provided a priority review.</li></ul>DBV Technologies (DBVT) said on Tuesday that its late-stage trial evaluating Viaskin Peanut patch for the treatment of peanut allergy in children resulted in significant drop in sensitivity, causing the stock to soar 63% after hours.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://dbv-technologies.com/press_releases/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskin-peanut-patch-in-peanut-allergic-children-aged-4-7-years/">said</a> that the patch demonstrated a statistically significant treatment effect in children aged 4 to 7 years with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder criteria after 12 months as compared to just 14.8% children who received placebo. The trial enrolled 654 children, more than the target enrollment of 600, who were then randomised to receive the patch or a placebo.According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful and represent substantial progress towards a well-tolerated, non-invasive potential option.”<h2 class="st-heading-2">Safety Results</h2>Safety results were also consistent with the profile observed in previous trials, the company said.Discontinuations due to adverse effects was 3.2% in patients who received the Viaskin Peanut patch as compared to 0.5% in the placebo arm, it added. While two children expected treatment-related serious adverse events and treatment-related anaphylaxis, they continued treatment, the company said. &nbsp;<h2 class="st-heading-2">Looking Forward</h2>The France-headquartered company, which seeks to develop treatment options for food allergies, now plans to submit an application to the U.S. Food and Drug Administration seeking approval for Viaskin Peanut in the first half of 2026.The company expects its application might be provided a priority review, provided that Viaskin Peanut patch was granted Breakthrough Therapy Designation by the FDA.VIASKIN patch is designed to introduce microgram amounts of an allergen like peanuts to the immune system through intact skin to induce tolerance. The company is also studying the patch in peanut allergic toddlers of 1 through 3 years of age and expects to seek approval for the patch in the age group in the second half of 2026 upon completion of trials.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DBVT stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.A Stocktwits user highlighted a huge market opportunity, citing the large number of people who are allergic to nuts.<stembedurl>https://www.stocktwits.com/Mushichka/message/639370968</stembedurl>Another sees the stock flying to the moon. “Must be mad crackers if you are even considering shorting this,” they added.<stembedurl>https://www.stocktwits.com/ghcb1981/message/639370886</stembedurl><a href="https://stocktwits.com/symbol/DBVT">DBVT stock</a> has multiplied by about 6 times this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-hits-all-time-high-on-robotaxi-optimism-europe-battery-plans-add-tailwind/cLeJnpgREpg">Tesla Hits All-Time High On Robotaxi Optimism As Wall Street Sees Path To $3T Valuation — Europe Battery Plans Add Tailwind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the DBV Technologies logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful.”

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.29
Prev Close	$10.65
Open	$9.35
Dividend Yield	0.00%
50-Day Moving Average	$11.62
Beta	0.46
Avg. Volume	349,915.17
PE Ratio	-3.41

52-Week High	$26.19
52-Week Low	$8.63
Market Capitalization	$646.71M
EPS (Annual)	-$5.28
Price to Book	4.35
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DBVT Fundamentals